* Says FDA lifts clinical hold on human trial application
* Shares up 17 pct in pre-market
July 30 Geron Corp (GERN.O) said the U.S.
health regulator allowed it to proceed with an early stage
trial on its experimental stem cell therapy for acute spinal
cord injury, sending its shares up 17 percent in pre-market
In August last year, Geron's GRNOPC1 had run into safety
problems during the animal study stage, prompting the U.S. Food
and Drug Administration to place a clinical hold on its
investigational new drug application for the therapy.
On Friday, the company said the clinical hold on its
application has been lifted.
Shares of the stem cell research company rose 17 percent to
$5.60 in pre-market trade. They closed at $4.80 Thursday on
(Reporting by Shailesh Kuber in Bangalore; Editing by Anne